We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -4.88% | 4.875 | 4.75 | 5.00 | 5.125 | 4.875 | 5.125 | 630,501 | 14:14:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.09 | 5.61M |
TIDMGDR
RNS Number : 7697D
Genedrive PLC
24 October 2022
24 October 2022
genedrive plc
("genedrive" or the "Company")
Grant of Options
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that on 21 October 2022 share options ("Options") were granted to members of its senior management team to acquire a total of 400,000 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price of 12.25p being equal to the closing price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending 30 June 2025. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. Details of the person discharging managerial responsibilities / person closely associated a. Name 1. Sarah Barnett 2. Jonathan Barber 3. Gino Miele 4. Colleen Phythian --------------------- -------------------------------------------------- 2. Reason for the notification ------------------------------------------------------------------------- a. Position/status 1. Marketing Director 2. Operations Director 3. R&D Director 4. Director of Quality & Regulation --------------------- -------------------------------------------------- a. Initial notification Initial notification /Amendment --------------------- -------------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------- a. Name genedrive plc --------------------- -------------------------------------------------- b. LEI 213800ZYODIRZ87Y4K14 --------------------- -------------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------- a. Description Options over ordinary shares of 1.5 pence of the each Financial instrument, type of instrument GB00B1VKB244 Identification code --------------------- -------------------------------------------------- b. Nature of Grant of options pursuant to and in accordance the transaction with the terms of the Company's Share Option Scheme dated 29 November 2017 --------------------- -------------------------------------------------- c. Price(s) and volume(s) PDMR Exercise No of Options price --------- -------------- Sarah Barnett 12.25p 100,000 --------- -------------- Jonathan Barber 12.25p 100,000 --------- -------------- Gino Miele 12.25p 100,000 --------- -------------- Colleen Phythian 12.25p 100,000 --------- -------------- --------------------- -------------------------------------------------- d. Aggregated information N/A Aggregated volume Price --------------------- -------------------------------------------------- e. Date of the 21 October 2022 transaction --------------------- -------------------------------------------------- f. Place of the Outside a trading venue transaction --------------------- --------------------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245 David Budd: CEO / Russ Shaw: CFO Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900 James Steel / Oliver Duckworth finnCap (Joint Broker) +44 (0)20 7220 500 Geoff Nash / George Dollemore / Nigel Birks / Alice Lane Walbrook PR Ltd (Media Relations +44 (0)20 7933 8780 or genedrive@walbrookpr.com & Investor Relations) Anna Dunphy +44 (0)7876 741 001
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHMBBATMTTTBTT
(END) Dow Jones Newswires
October 24, 2022 02:00 ET (06:00 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions